Rheumatoid arthritis - tocilizumab (rapid review TA198)
| Status: |
History |
| Expected date of issue: |
February 2012 |
| Referral date: |
July 2008 |
| Wave: |
18 |
| Process: |
STA |
| Notes:
This STA is following the rapid review process
|
| Topic area:
|
NICE project team
| Executive Lead: |
Andrew Dillon
|
| Technical Lead: |
Emma Stewart
|
| Communications manager: |
Tonya Gillis
|
| Project manager: |
Lori Farrar
|
Provisional schedule
| Closing date for invited submissions / evidence submission: |
Not applicable for this topic |
| 1st appraisal committee meeting: |
14 September 2011 |
| 2nd appraisal committee meeting |
08 November 2011 |
Consultees and commentators
|
| Consultees |
Commentators (no right to submit or appeal) |
|
Manufacturers/sponsors
- Roche Products (tocilizumab)
Patient/carer groups
- Arthritis & Musculoskeletal Alliance (ARMA)
- Arthritis Care
- National Rheumatoid Arthritis Society
Professional groups
- British Health Professionals in Rheumatology
- British Society for Rheumatology
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
Others
- Department of Health
- Welsh Assembly Government
|
General
- Department of Health, Social Services and Public Safety for Northern Ireland
- NHS Quality Improvement Scotland
Possible comparator manufacturer(s)
- Abbott Laboratories (adalimumab)
- AstraZeneca UK (chloroquine)
- GlaxoSmith Kline (azathioprine)
- Novartis (ciclosporin)
- Pfizer (methotrexate, sulfasalazine, etanercept)
- Roche Products (rituximab)
- Sanofi Aventis (hydroxychloroquine, leflunomide, sodium aurothiomalate)
- Schering-Plough (infliximab)
Relevant research groups
Evidence Review Group
- West Midlands Health Technology Assessment Collaboration
- National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme)
Associated guideline groups
Associated public health groups
|
|
Key documents
This page was last updated: 20 February 2012
